Zack’s increases its price target on this stock after a blow out quarter.
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Huge Alerts.
 Not long ago BSEM released its 2Q 2024 earnings results, which vastly exceeded estimates as revenue growth accelerated!
The biotech space staged a comeback in late 2023 and early 2024 as Big Pharma tapped into takeovers again. In mid-July biotech tech stocks even hit a two-year high. One biotech company with exciting developments that may be going underfollowed is BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care. According to Zacks, the average 12-month price target for BioStem Technologies, Inc. (BSEM) is $24.25! Why might Zack’s Small Cap Research be so bullish on BSEM with a $24.25 price target? Stellar financial results is one reason and another may be because a study published in a peer-reviewed journal finds BioStem’s products offer overall better treatment efficiency and greater efficiency in general wound closure. Regenerative medicine is one of the most exciting arenas in medicine and BSEM is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. Last month BSEM announced that the Institutional Review Board (IRB) has approved a clinical study to evaluate its Vendaje® product for diabetic foot ulcers (DFU), a key product in the company’s placental-derived allograft portfolio. This study aims to assess the efficacy of Vendaje compared to standard of care in diabetic patients with non-healing DFU’s, providing critical data to support both patient outcomes and payer decisions. Diabetic Foot Ulcers are a significant risk for people with diabetes. According to the American Podiatric Medical Association (APMA), a leading resource for foot and ankle health, approximately 15 percent of people with diabetes develop foot ulcers. Of those 15 percent, six percent go on to be hospitalized due to infection or other ulcer-related complications. The risk to patients with diabetes is significant, as it is the leading cause of lower extremity amputations in the U.S. Discover more about BSEM and its superior product for treating diabetic foot ulcers and how this could build shareholder value for investors! Huge Alerts |
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of BioStem Technologies Inc. (OTC: BSEM). The compensation consists of up to $2,500 and was received/will be received from Sideways Frequency. This compensation should not be considered as an endorsement of the securities of adviser BioStem Technologies Inc. (OTC: BSEM) and we are not responsible for any errors or omissions in any information provided about the securities of BioStem Technologies Inc. (OTC: BSEM) made by Huge Alerts. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 10/22/24. Behind the Markets
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
Unsubscribe
|
|
Tidak ada komentar:
Posting Komentar